Blueprint Medicines Announces R&D Leadership Transitions
"As our first Chief Medical Officer, Andy has been a key driver in establishing
Dr. Namouni added, "We're thankful for the major contributions Marion has made toward building our industry-leading precision therapy pipeline, including the advancement of two new molecular entities into clinical trials and the nomination of five development candidates under her leadership, and we wish her well in her future endeavors. As we move forward, we plan to deepen our focus on precision medicine, building on a decade of R&D innovation, by combining our highly productive scientific platform with an expanded R&D vision embracing new precision therapy modalities."
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-rd-leadership-transitions-301204816.html
Investor Contact, Kristin Hodous, 617-714-6674, email@example.com OR Media Contact, Andrew Law, 617-844-8205, firstname.lastname@example.org